-
Platelet/Neutrophil Count Ratio (PNR) and Fibrinogen/Lymphocyte Count Ratio (FLR) Can Be Used as Predictive Indicators of Bone Metastasis in Non-Smoking Patients with Lung Cancer, but Not in Smoking Patients
10 Sep 2025 15:20 GMT
… of Lung Cancer Patients and Comparison of Lung Cancer Patients … of Lung Cancer Patients and Comparison of Lung Cancer Patients … in Patients with Lung Cancer
Discussion
Primary lung cancer is a … 2 viral oncogene homolog (KRAS) mutations) and a …
-
Lung Cancer: 5 Things to Know
09 Sep 2025 14:17 GMT
… to know about lung cancer.
1. Lung cancer encompasses diverse … -small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). … redefining lung cancer treatment.
The therapeutic landscape for lung cancer … with brain metastases. KRAS G12C inhibitors such …
-
What Patients With Lung Cancer Need to Know About KRAS G12C Mutations
09 Sep 2025 01:16 GMT
… KRAS G12C mutations can be very important for patients with lung cancer … 14% of patients with lung cancer. It matters, because … Lung Cancer in Barcelona.
Transcript
Can you explain what KRAS … these patients with advanced lung cancer?
KRAS G12C is a [genetic …
-
Overcoming Resistance Mutations and the Blood–Brain Barrier: Major Challenges in Targeted Therapy for Brain Metastases in Non-Small Cell Lung Cancer
08 Sep 2025 21:42 GMT
… metastatic non-small cell lung cancer (NSCLC). Despite significant … fusions, and the emerging KRAS^G12C mutations has extended … metastatic non-small cell lung cancer, focusing on resistance … metastatic non-small cell lung cancer
News Publication Date: …
-
Eli Lilly gets USFDA Breakthrough Therapy designation for olomorasib with Keytruda for lung cancer
07 Sep 2025 13:32 GMT
… non-small cell lung cancer (NSCLC) with a KRAS G12C mutation and … second-generation inhibitor of KRAS G12C with preliminary evidence … the 2025 World Conference on Lung Cancer (WCLC) hosted by … Association for the Study of Lung Cancer (IASLC), taking place Sept …
-
Emerging Targets in Non-Small Cell Lung Cancer
06 Sep 2025 06:12 GMT
… lung cancer (NSCLC) represents approximately 85% of all lung cancer … targeting KRAS G12C, targeting other KRAS mutations, particularly KRAS G12D … models of KRAS G12D mutated lung cancer and is … advanced non-small cell lung cancer. Lung Cancer. 2023;182:107291 …
-
Pan-Immune-Inflammation Value (PIV) and Prognostic Nutritional Index (PNI) are Associated with Distant Metastasis in Colorectal Cancer with KRAS Mutation but Not in Those with KRAS Wild-Type
10 Sep 2025 15:22 GMT
… , et al. Advanced lung cancer inflammation index predicts outcomes … defactinib in KRAS-mutated non-small cell lung cancer. Br … cycle induces ferroptosis in KRAS-mutant lung cancer. Nat Commun. … is required for mutant KRAS lung tumorigenesis. Cell Rep. 2016 …
-
FDA Grants Breakthrough Therapy to Olomorasib in Lung Cancer Subset
05 Sep 2025 16:51 GMT
… non-small cell lung cancer with a KRAS G12C mutation and … 2025 World Conference on Lung Cancer (WCLC) hosted by … certain newly diagnosed metastatic KRAS G12C-mutant lung cancers,” news release, Sept … -combo-is-safe-for-lung-cancer-subset
“Study of Olomorasib …
-
Lilly’s Olomorasib Gets FDA Breakthrough Therapy Nod for New Metastatic KRAS G12C Lung Cancer Treatment
05 Sep 2025 16:39 GMT
… non-small cell lung cancer (NSCLC) harboring the KRAS G12C mutation … generation inhibitor targeting the KRAS G12C mutation, with early … better treatment options for KRAS G12C-mutant NSCLC patients, … the 2025 World Conference on Lung Cancer (WCLC) in Barcelona, …
-
US FDA grants Breakthrough Therapy designation to Lilly's olomorasib to treat certain newly diagnosed metastatic KRAS G12C─mutant lung cancers
05 Sep 2025 08:59 GMT
… non-small cell lung cancer (NSCLC) with a KRAS G12C mutation and … the 2025 World Conference on Lung Cancer (WCLC) hosted by the … Association for the Study of Lung Cancer (IASLC), taking place September … inhibitor of the KRAS G12C protein. KRAS is the most …
About
© 1995-2025